Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 469 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IV Non-Small Cell Lung Cancer AJCC v7 Clear all
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NCT00019435
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ipilimumab, Erlotinib, Crizotinib, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 13, 2026, 7:10 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
Interventions
Ceritinib, Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00003587
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 13, 2026, 7:10 PM EDT
Withdrawn Phase 2 Interventional

Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

NCT03121417
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Nivolumab
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 13, 2026, 7:10 PM EDT
Terminated Phase 1 Interventional

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01249443
View directory record Official record
Conditions
HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
vorinostat, diagnostic laboratory biomarker analysis, pharmacological study, carboplatin, paclitaxel
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 13, 2026, 7:10 PM EDT
Terminated Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

NCT00039091
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Melanoma, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 13, 2026, 7:10 PM EDT
Terminated Phase 1 Interventional

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

NCT00088933
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer, Recurrent Small Cell Lung Cancer, Stage IV Colon Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Rectal Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 13, 2026, 7:10 PM EDT
Terminated Phase 1 Interventional

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

NCT02298153
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
Interventions
Epacadostat, Atezolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 13, 2026, 7:10 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT00323362
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, imatinib mesylate
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 13, 2026, 7:10 PM EDT
Withdrawn Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00054392
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
57
States / cities
Loma Linda, California • Pomona, California • New London, Connecticut + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 13, 2026, 7:10 PM EDT
Recruiting Phase 1 Interventional

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

NCT07619599
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 13, 2026, 7:10 PM EDT
Withdrawn Phase 1 Interventional

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

NCT02451865
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Binimetinib, Docetaxel, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 13, 2026, 7:10 PM EDT
Active, not recruiting No phase listed Observational

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

NCT04056247
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
Interventions
Plasma sample collection
Other
Lead sponsor
OncoHost Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00008333
View directory record Official record
Conditions
Lung Cancer
Interventions
vinorelbine tartrate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
13
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Pharmacological Ascorbate for Lung Cancer

NCT02420314
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer

NCT00408499
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cetuximab, erlotinib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00104767
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer

NCT00004178
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 13, 2026, 7:10 PM EDT
Terminated Phase 3 Interventional Results available

Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer

NCT00387348
View directory record Official record
Conditions
Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
Interventions
escitalopram oxalate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 2 Interventional

10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00004238
View directory record Official record
Conditions
Lung Cancer
Interventions
pralatrexate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

NCT01234038
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ISIS EIF4E Rx, Paclitaxel, Carboplatin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Hot Springs, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 13, 2026, 7:10 PM EDT